Stock ERIS ERIS LIFESCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:56 2024-06-03 am EDT 		5-day change 1st Jan Change
914.3 INR -0.21% Intraday chart for Eris Lifesciences Limited +4.09% +0.41%
May. 22 Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit MT
May. 21 Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88,687 50,089 82,147 93,615 77,801 124,454 - -
Enterprise Value (EV) 1 88,687 50,089 82,147 93,615 85,984 128,066 149,761 143,673
P/E ratio 30.5 x 17.1 x 23.1 x 23 x 20.4 x 29.3 x 31 x 22.4 x
Yield - 0.62% 0.91% 0.87% 1.28% 0.78% 0.75% 1.01%
Capitalization / Revenue 9.03 x 4.66 x 6.78 x 6.95 x 4.62 x 5.71 x 4.18 x 3.82 x
EV / Revenue 9.03 x 4.66 x 6.78 x 6.95 x 5.1 x 6.37 x 5.04 x 4.41 x
EV / EBITDA 25.7 x 13.6 x 19.1 x 19.3 x 16 x 19 x 14.6 x 12.3 x
EV / FCF 47.9 x 41.8 x 23.5 x 36.4 x -15.6 x 35.9 x -14.2 x 21.9 x
FCF Yield 2.09% 2.39% 4.26% 2.75% -6.39% 2.79% -7.05% 4.56%
Price to Book 7.71 x 3.86 x 5.21 x 4.91 x 3.54 x 4.44 x 4.22 x 3.69 x
Nbr of stocks (in thousands) 137,520 135,781 135,781 135,930 135,992 136,053 - -
Reference price 2 644.9 368.9 605.0 688.7 572.1 914.8 914.8 914.8
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 5/21/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 9,822 10,741 12,119 13,470 16,851 20,091 29,743 32,612
EBITDA 1 3,449 3,683 4,306 4,850 5,367 6,748 10,252 11,718
EBIT 1 3,086 3,180 3,876 4,202 4,197 4,922 7,369 8,822
Operating Margin 31.42% 29.61% 31.98% 31.2% 24.9% 24.5% 24.78% 27.05%
Earnings before Tax (EBT) 1 3,174 3,315 3,945 4,422 4,046 4,312 5,461 7,450
Net income 1 2,908 2,963 3,551 4,061 3,822 3,920 4,075 5,577
Net margin 29.61% 27.59% 29.3% 30.15% 22.68% 19.51% 13.7% 17.1%
EPS 2 21.13 21.58 26.14 29.88 28.07 28.79 29.50 40.85
Free Cash Flow 1 1,850 1,198 3,496 2,572 -5,497 3,568 -10,554 6,548
FCF margin 18.84% 11.16% 28.85% 19.1% -32.62% 17.76% -35.48% 20.08%
FCF Conversion (EBITDA) 53.63% 32.54% 81.19% 53.04% - 52.88% - 55.88%
FCF Conversion (Net income) 63.62% 40.44% 98.44% 63.34% - 91.04% - 117.42%
Dividend per Share 2 - 2.287 5.500 6.010 7.350 7.155 6.900 9.277
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 5/21/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3,104 2,782 3,437 3,597 3,322 3,059 3,986 4,605 4,233 4,028 4,666 5,094 4,825 5,130
EBITDA 1 1,072 945.2 1,265 1,398 1,217 969 1,292 1,514 1,372 1,189 1,697 1,819 1,740 1,788
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 993 847.3 1,171 1,308 1,090 853.4 1,013 1,209 1,065 759 1,125 1,288 1,195 1,102
Net income 1 901.5 682.5 1,067 1,184 1,008 803 945.8 1,203 1,019 654.2 948.6 1,088 1,022 912.4
Net margin 29.04% 24.53% 31.04% 32.92% 30.34% 26.25% 23.73% 26.12% 24.07% 16.24% 20.33% 21.36% 21.18% 17.78%
EPS - - - - - - - - - - - 7.880 - 6.600
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 1/28/21 5/13/21 7/29/21 10/29/21 1/28/22 5/3/22 8/5/22 10/20/22 1/17/23 5/17/23 8/7/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 8,183 13,346 25,307 19,219
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) - - - - 1.524 x 1.978 x 2.468 x 1.64 x
Free Cash Flow 1 1,850 1,198 3,496 2,572 -5,497 3,568 -10,554 6,548
ROE (net income / shareholders' equity) 28.9% 24.2% 24.7% 23.3% 18.6% 16.4% 14.1% 17.5%
ROA (Net income/ Total Assets) - 19.1% - - 12.9% 7.32% 9.95% 12%
Assets 1 - 15,535 - - 29,697 53,581 40,938 46,574
Book Value Per Share 2 83.70 95.50 116.0 140.0 161.0 190.0 217.0 248.0
Cash Flow per Share 2 - - 27.60 27.80 21.40 35.70 49.50 65.20
Capex 1 374 1,513 258 1,210 8,414 1,292 15,240 1,972
Capex / Sales 3.81% 14.09% 2.13% 8.99% 49.93% 6.43% 51.24% 6.05%
Announcement Date 5/21/19 6/2/20 5/13/21 5/3/22 5/17/23 5/21/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eris Lifesciences Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
914.8 INR
Average target price
1,092 INR
Spread / Average Target
+19.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.60% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.74% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.79% 318B
ABBVIE INC. Stock AbbVie Inc.
+3.37% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 240B
NOVARTIS AG Stock Novartis AG
+9.26% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 206B
AMGEN INC. Stock Amgen Inc.
+6.74% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ERIS Stock
  4. ERIS Stock
  5. Financials Eris Lifesciences Limited